logo-loader
viewTHC Global Group Ltd

THC Global is all licensed up and ready to go: MST Access

THC has the potential to cultivate cannabis in over 100,000 square metres of hydroponic greenhouse facilities in Australia at its Bundy, Eden Farms and Ballina sites.

THC Global Group Ltd - THC Global is all licenced up and ready to go: MST Access
MST Access has valued THC at 81 cents per share

THC Global Group Ltd (ASX:THC) recently secured a licence to manufacture therapeutic goods at its Southport Facility, completing all licences required to commence the manufacture of medicinal cannabis.

MST Access has initiated coverage on THC with a 12 month forward base case valuation of 81 cents.

Following is an extract from MST’s research report:

FY2020 – Transitioning to growth

With the first bottling of its medicinal cannabis oil in early December at its Southport Therapeutic Goods Administration (TGA) approved good manufacturing practice (GMP) pharmaceuticals biomanufacturing facility, THC Global (THC) has validated its locally grown “biomass to bottle” processing capability. THC is now able to accept feedstock from any licensed permitted cultivator, or its own cultivation operations, to produce cannabinoid oil to sell domestically or export globally.

All licensed up and ready to go

The TGA has granted THC a license for the commercial manufacture of therapeutic goods (GMP License) at the Southport facility. By the end of 1Q CY2020 we forecast THC will have met all the required product validation tests on the cannabidiol (CBD) oil being produced at Southport and will have received the final TGA approval allowing THC to sell that product into the market.

By mid CY2020 we forecast THC will receive its Office of Drug Control (ODC) license to cultivate at Eden Farms. We forecast limited production in CY2020 from Eden Farms with the site ramping up to 66,000 m2by the end of CY2024.

Flexible business model

THC has the potential to cultivate cannabis in over 100,000m2 of hydroponic greenhouse facilities in Australia at its Bundy, Eden Farms and Ballina sites; i.e. “farm to pharma”.

Alternatively, it may look to source lower cost cannabis biomass and imported crude cannabis oil from other licensed permitted cultivators to put through its TGA GMP approved site. This follows on from the decision by the ODC to allow appropriately licensed and permitted organisations to import cannabis material, including extracts, for use in manufacture. This would allow THC to utilise the capacity at its Southport facility while cultivation at Eden Farms ramps up.

Given the Southport facility has clearance from the TGA as a GMP site, THC is capable of exporting lower cost cannabinoid product to globally approved markets that have reciprocal agreements with Australia.

Valuation

Our 12 month forward base case valuation is $0.81 on an adjusted diluted basis. We have THC ramping up its hydroponic cultivation to ~67,200 m2 by the end of CY2024 in line with how fast we believe THC can grow product sales.

Clearly if THC can ramp up production and sales faster than we are forecasting there is upside in our valuation. If THC was cultivating and selling 67,200 m2 of hydroponic greenhouse cannabis by the end of CY2022, our valuation lifts to $0.94.

Quick facts: THC Global Group Ltd

Price: 0.26 AUD

ASX:THC
Market: ASX
Market Cap: $45.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of THC Global Group Ltd named herein, including the promotion by the Company of THC Global Group Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 29/1/20

3 min read